Brolucizumab: where the agencies disagree
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
AOTMIT (Poland), HIRA (South Korea) and NICE (England), among others, recommended or restricted brolucizumab, while CIPM (Spain) and NYE METODER (Norway) did not recommend it.
The record spans 4.8 years, opening at PBAC (Australia) in 2019 and running to 2 May 2024.
DMC (Denmark) changed its position: not recommended on 3 Jul 2020, recommended by 8 Mar 2023, after a resubmission.
No assessment is on file from PHARMAC (New Zealand) and TLV (Sweden), each among the eight highest-volume agencies here.
The file is active: 4 of 24 records date from 2023 or later.
7 distinct indication wordings are recorded for brolucizumab by the agencies that label one in English (AWMSG, NICE, PBAC and SMC).
4 of these 24 records carry a year of decision but no day, so any interval quoted here is approximate to within a year.
PBAC (Australia) was first to assess brolucizumab, in 2019; G-BA (Germany) did not open a file until 20 Oct 2022 — a wide spread of 3.2 years between the earliest and latest system to look at it.
The record arrives in waves: 4 separate years each carry two or more decisions, spread across 6 years in total.
Restriction is doing real work here: 5 of 18 decisive outcomes narrowed brolucizumab to a subgroup rather than accepting or refusing it outright, at AOTMIT (Poland), HIRA (South Korea) and NICE (England) among others.
9 of the 11 agencies here assessed brolucizumab more than once, PBAC (Australia) most often at 4 entries — repeat review is the norm for this molecule rather than the exception.
11 of the 18 agencies in this archive hold a record for brolucizumab.
The full ledger for brolucizumab reads 9 not recommended, 5 restricted, 4 recommended and 2 no benefit, with 4 in other categories.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| G-BA (Germany) | 2 May 2024 | Beovu — benefit assessment §35a | added benefit: not proven | source |
| HAS (France) | 5 Jul 2023 | Change to listing conditions (Transparency Committee) | SMR insufficient · ASMR V | source |
| DMC (Denmark) | 8 Mar 2023 | Diabetisk makulaødem (DME) | Direkte indplacering | source |
| CIPM (Spain) | 2 Feb 2023 | Indicaciones terapéuticas autorizadas: Beovu está indicado en adultos para el tratamiento de: la degeneración macular … | not financed by the SNS · art. 92 d, e | source |
| NYE METODER (Norway) | 20 Nov 2022 | Behandling av voksne med nedsatt syn som skyldes diabetisk makulaødem. | not introduced | source |
19 further decisions for brolucizumab, across 11 agencies, are not shown here. They link to 14 further source documents.
Related molecules
- faricimab — divergent outcome (not recommended vs recommended) on a shared indication
- aflibercept — divergent outcome (not recommended vs recommended) on a shared indication
- ranibizumab — divergent outcome (not recommended vs recommended) on a shared indication
- polatuzumab vedotin — also decided by G-BA in 2024Q2
- cannabidiol — also decided by G-BA in 2024Q2
- vosoritide — also decided by G-BA in 2024Q2
Coverage: 24 decisions for brolucizumab from 11 agencies, 2019 to 2024. Data to 7 Sep 2026. ATC class S01 — Ophthalmologicals. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.